Agenus Inc.

2.62-0.0400-1.50%Vol 2.86M1Y Perf 0.57%
Apr 16th, 2021 16:00 DELAYED
BID2.61 ASK2.62
Open2.65 Previous Close2.66
Pre-Market- After-Market2.62
 - -  - -%
Target Price
7.50 
Analyst Rating
Strong Buy 1.00
Potential %
- 
Finscreener Ranking
★★★★     53.40
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     38.80
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     57.96
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap536.27M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
9.26 
Earnings Date
6th May 2021

Today's Price Range

2.552.66

52W Range

2.285.95

5 Year PE Ratio Range

-2.30-3.10

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-5.76%
1 Month
-18.89%
3 Months
-21.79%
6 Months
-40.18%
1 Year
0.57%
3 Years
-35.94%
5 Years
-38.93%
10 Years
-52.54%

TickerPriceChg.Chg.%
AGEN2.62-0.0400-1.50
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
ProfitabilityValueIndustryS&P 500US Markets
-257.60
-138.20
-130.00
-313.30
-74.73
RevenueValueIndustryS&P 500US Markets
73.04M
0.36
86.77
38.82
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.22-0.209.09
Q03 2020-0.26-0.28-7.69
Q02 2020-0.27-0.28-3.70
Q01 2020-0.35-0.3111.43
Q04 2019-0.41-0.2246.34
Q03 2019-0.38-0.3313.16
Q02 2019-0.33-0.38-15.15
Q01 2019-0.300.12140.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.31-29.17Negative
6/2021 QR-0.29-16.00Negative
12/2021 FY-1.22-15.09Negative
12/2022 FY-1.25-22.55Negative
Next Report Date6th May 2021
Estimated EPS Next Report-0.31
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume2.86M
Shares Outstanding204.69M
Trades Count24.72K
Dollar Volume8.84M
Avg. Volume3.59M
Avg. Weekly Volume4.08M
Avg. Monthly Volume4.12M
Avg. Quarterly Volume3.89M

Agenus Inc. (NASDAQ: AGEN) stock closed at 2.62 per share at the end of the most recent trading day (a -1.5% change compared to the prior day closing price) with a volume of 2.88M shares and market capitalization of 536.27M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 328 people. Agenus Inc. CEO is Garo H Armen.

The one-year performance of Agenus Inc. stock is 0.57%, while year-to-date (YTD) performance is -17.61%. AGEN stock has a five-year performance of -38.93%. Its 52-week range is between 2.28 and 5.95, which gives AGEN stock a 52-week price range ratio of 9.26%

Agenus Inc. currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 49.72, a price-to-sale (PS) ratio of 7.50, a price to cashflow ratio of 116.70, a PEG ratio of 2.32, a ROA of -94.43%, a ROC of -% and a ROE of 80.67%. The company’s profit margin is -74.73%, its EBITDA margin is -130.00%, and its revenue ttm is $73.04 Million , which makes it $0.36 revenue per share.

Of the last four earnings reports from Agenus Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.31 for the next earnings report. Agenus Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Agenus Inc. is Strong Buy (1), with a target price of $7.5, which is 0.00% compared to the current price. The earnings rating for Agenus Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Agenus Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Agenus Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 23.00, ATR14 : 0.27, CCI20 : -124.43, Chaikin Money Flow : -0.34, MACD : -0.41, Money Flow Index : 36.30, ROC : -2.96, RSI : 30.59, STOCH (14,3) : 12.28, STOCH RSI : 0.67, UO : 36.88, Williams %R : -87.72), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Agenus Inc. in the last 12-months were: Allison M. Jeynes-Ellis (Option Excercise at a value of $0), Brian Corvese (Option Excercise at a value of $0), Timothy R. Wright (Option Excercise at a value of $0), Ulf Wiinberg (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Agenus Inc.

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others.

CEO: Garo H Armen

Telephone: +1 781 674-4400

Address: 3 Forbes Road, Lexington 02421-7305, MA, US

Number of employees: 328

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

71%29%

Bearish Bullish

62%38%

Bearish Bullish

58%42%

News

Stocktwits